Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acoydase-Cold is a multi-ingredient oral symptomatic cold formulation developed by Bernard Biotech. It is designed to provide comprehensive relief from symptoms associated with the common cold, influenza, and allergic rhinitis. The formulation combines five active pharmaceutical ingredients: aceclofenac, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce pain and inflammation; paracetamol, an analgesic and antipyretic that provides additional pain relief and fever reduction; cetirizine hydrochloride, a second-generation antihistamine that antagonizes H1 receptors to alleviate allergic symptoms like sneezing and runny nose; phenylephrine hydrochloride, a decongestant that acts as an alpha-1 adrenergic receptor agonist to reduce nasal congestion; and caffeine, which serves as a mild stimulant and adenosine receptor antagonist, often used to enhance the analgesic effects of the other components and counteract drowsiness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclofenac + paracetamol + cetirizine + phenylephrine + caffeine.